Publication:

Efficacy of a novel supplement GlucoSEB PB™ for glucose management: an in vitro and clinical study approach

Background The objective of the study was to perform a comprehensive investigation of GlucoSEB PB™ using in-vitro digestion and a clinical study for evaluating its effects on sugar digestion and associated metabolic responses.

Methods In-vitro digestion of a bread-chicken-patty as a food-matrix was performed using INFOGEST simulated semi-dynamic digestion protocol in presence and absence of GlucoSEB PB™. The sugars released were quantified. Further, for the clinical trial, a double-blind, randomized, crossover, placebo-controlled study was performed by randomizing 35-prediabetic subjects into test and placebo groups. Subjects were instructed to consume 2-capsules (test or placebo), 30-min prior to consumption of standard-meal, and blood-glucose related parameters were monitored.

Results GlucoSEB PB™ effectively caused a net reduction in the available simple-sugars by 19.40% post in-vitro gastro-intestinal digestion. This was due to formation of oligosaccharides with dietary-fiber potential conferring prebiotic benefits. The findings of the clinical-study indicated an increase in blood-glucose levels until 45 and 60-min in the GlucoSEB PB™ and placebo groups, followed by a continuous decline for 3-h post-consumption of the standard-meal. GlucoSEB PB™ supplementation resulted in a 16.90% reduction in AUC over the placebo, signifying its role in controlling blood-glucose. Additionally, no variations were observed in insulin levels in both arms.

Conclusion Notably, GlucoSEB PB™ was safe and showcased tolerability at the investigated dosage. No AEs/SAEs were reported during the entire investigation.